WinstrolStanozolol — Oral & Injectable DHT AAS Research Reference by QSC Peptides

Stanozolol (Winstrol) is a DHT derivative with a uniquely modified A-ring — a pyrazole ring has been fused at the 2,3-position, creating 17α-methyl-5α-androstano[3,2-c]pyrazol-17β-ol. This makes stanozolol the only AAS with a pyrazole ring structure, conferring distinctive pharmacological properties.

The pyrazole modification prevents aromatization and produces a receptor binding profile distinct from other DHT derivatives. Stanozolol also notably does not bind the sex hormone-binding globulin (SHBG) — or rather, it displaces testosterone from SHBG binding, increasing free testosterone availability in research models.

Oral vs Injectable — Unique Kinetics

Stanozolol is unusual in that both its oral and injectable forms are 17α-alkylated (unlike testosterone where the injectable avoids first-pass). The injectable aqueous suspension is the same molecule as the tablets, not an ester. This means injectable Winstrol's half-life (~24 hours) is primarily determined by its aqueous depot absorption rate, not ester hydrolysis.

SHBG Displacement Research

Stanozolol binds SHBG with high affinity and can displace other steroids, increasing the free fraction of co-administered AAS. This makes it a valuable tool in research on SHBG binding competition, free vs bound steroid activity, and multi-compound pharmacokinetic studies.